比较Venefit、射频诱导热疗与静脉内射频消融治疗大隐静脉功能不全的随机临床试验六年扩展研究
对3RF随机试验中接受Venefit、RFITT或EVRF治疗大隐静脉功能不全的患者进行72个月随访,评估闭合失败率及患者报告结局。Venefit与RFITT的长期技术结局显著优于EVRF,但生活质量评分组间无差异,患者报告任何静脉曲张的比例均较高。
要点
- 72个月超声示大隐静脉闭合失败率Venefit 16%、RFITT 21%、EVRF 37%(p=.14),所有失败结局分别为14%、17%、44%(p<.001)。
- Venefit与RFITT在全部失败结局上均显著优于EVRF(均p<.001),Venefit与RFITT间无显著差异(p=.63)。
- AVVQ与EQ-5D评分组间无差异,患者报告任何静脉曲张比例三组均高(97%、92%、97%,p=.48)。
核心结论
- 大隐静脉射频消融的长期技术结局Venefit与RFITT显著优于EVRF,但72个月生活质量评分无差异,患者报告任何静脉曲张比例均高。
研究设计与样本
- 3RF随机试验的72个月随访研究,邀请172名参与者参加单次长期随访。
- 主要结局为双功能超声评估的大隐静脉闭合失败,次要结局包括AVVQ、EQ-5D及患者报告静脉曲张。
主要发现
- 22例(12%)已再治疗,余者中13例(7%)无法联系、20例(11%)拒绝邀请、1例未同意,最终116例(64%)完成问卷、95例(53%)完成双功能超声。
- 72个月双功能超声示大隐静脉闭合失败率Venefit 16%、RFITT 21%、EVRF 37%(p=.14)。
- 所有失败结局Venefit 14%、RFITT 17%、EVRF 44%(p<.001);Venefit vs EVRF p<.001,RFITT vs EVRF p<.001,Venefit vs RFITT p=.63。
- AVVQ与EQ-5D评分组间无差异;患者报告任何静脉曲张比例Venefit 97%、RFITT 92%、EVRF 97%(p=.48)。
- EVRF组患者报告静脉曲张复发范围较Venefit和RFITT组更广泛(p=.008)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare long term outcomes after great saphenous vein (GSV) treatment with three radiofrequency (RF) thermal devices: Venefit (Closurefast), Radiofrequency Induced Thermal Therapy (RFITT), and Endovenous Radiofrequency (EVRF). DESIGN: A 72 month follow up of patients who were treated in the randomised 3RF study. METHODS: A total of 172 participants from the 3RF study were invited to take part in a single visit, long term, follow up study. Failure of GSV closure was assessed with duplex ultrasound (DUS) and constituted the primary outcome. Patients completed questionnaires for secondary outcomes: Aberdeen Varicose Vein Questionnaire (AVVQ), Euroqol 5D (EQ-5D), and patient reported varicose veins measured by counting vein occupying boxes in AVVQ question 1. RESULTS: Twenty-two patients (12%) had already been re-treated. Of the remainder, 13 (7%) could not be contacted, 20 (11%) declined invitation, and one did not consent. Therefore, 116 (64%) and 95 (53%) participants completed questionnaires and DUS, respectively. Failure of GSV closure on 72 month DUS was 16%, 21%, and 37% for Venefit, RFITT, and EVRF, respectively (p = .14), whilst outcomes for all failures were 14%, 17%, and 44% (p < .001) (Venefit vs. EVRF: p < .001; RFITT vs. EVRF: p < .001; and Venefit vs. RFITT: p = .63). There were no between group differences in AVVQ or EQ-5D scores. Rates of patient reported presence of any varicose veins were high for all groups (97%, 92%, and 97% after Venefit, RFITT, and EVRF, respectively; p = .48). The EVRF treated participants reported more extensive recurrence than the Venefit and RFITT participants (p = .008). CONCLUSION: Long term technical outcomes after RF ablation for GSV varicose veins were significantly better after Venefit and RFITT compared with EVRF treatment. However, quality of life scores showed no differences after 72 months. Rates of patient reporting any varicose veins were high for all treatments. CLINICALTRIALS: gov Identifier: NCT04720027.
引用
- Nyamekye IK, Pullen BJ, Kelly N, et al. Six Year Extension Study of Patients From a Randomised Clinical Trial Comparing Venefit, Radiofrequency Induced Thermal Therapy, and Endovenous Radiofrequency Ablation for Treatment of Incompetent Great Saphenous Veins. Eur J Vasc Endovasc Surg. 2023. PMID: 36958479. doi:10.1016/j.ejvs.2023.03.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。